Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057239 · ClinicalTrials.gov registry record · Phase 2
An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 546
- Enrollment target
NCT00057239 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 546 participants.
The verdict
NCT00057239, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 546 participants
- Enrollment target
Study Summary
A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Radafaxine in Patients with Major Depressive Disorder (MDD)
Interventions
- DRUG Radafaxine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 546 participants |
| Start Date | 2003-03 |
| Est. Completion | 2004-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057239
The ClinicalTrials.gov registry entry for NCT00057239 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 546 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Radafaxine is the first listed.
NCT00057239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00057239 about?
NCT00057239 is a clinical study titled "An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder". A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Radafaxine in Patients with Major Depressive Disorder (MDD)
What is the current status of trial NCT00057239?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 546 participants. The study started on 2003-03. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00057239?
The interventions under investigation include: Radafaxine (DRUG).
Who is sponsoring clinical trial NCT00057239?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.